5 Takeaways From FDA Overture On Generic-Drug Approvals

Law360, New York (January 24, 2014, 8:05 PM EST) -- The U.S. Food and Drug Administration signaled Wednesday that it’s taking customer service to heart now that generic-drug makers are paying for faster approvals, inviting reform proposals that experts say industry will be more than happy to provide. 

In a request for comments, regulators cited more than two dozen “common, recurring deficiencies” in so-called abbreviated new drug applications and offered to address any root causes. While lawyers generally welcomed the agency’s offer, they also described it as merely a down payment on an overdue regulatory overhaul....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.